See the DrugPatentWatch profile for Romidepsin
What’s the price per vial of Romidepsin?
A single vial of Romidepsin (Istodax) typically costs around $10 000 to $12 000 in the United States. The drug is supplied in 30‑ml vials containing 4 mg, which is the standard dose used for patients with cutaneous T‑cell lymphoma (CTCL) or peripheral T‑cell lymphoma (PTCL).
How does that add up over a treatment cycle?
Romidepsin is usually given on a schedule of 2 weeks on, 2 weeks off, repeated over 12 weeks. A typical 12‑week cycle uses about four vials, so the wholesale cost for a single cycle can reach roughly $40 000–$48 000. Because many patients undergo multiple cycles, the total cost over a year can approach $200 000–$250 000, depending on the exact schedule and any dose adjustments.
Will insurance cover it, and what might my out‑of‑pocket cost be?
Most commercial insurance plans list Romidepsin as a covered drug, but patients usually face a copay, coinsurance, or deductible. Out‑of‑pocket costs can range from a few hundred to several thousand dollars per infusion, depending on the plan. Medicare Part D plans may cover the medication, but the exact benefit depends on the formulary and any prior‑authorship requirements.
Are there cheaper alternatives or biosimilars on the horizon?
Other histone deacetylase inhibitors, such as vorinostat (Zelboraf) or belinostat (Beleodaq), are typically less expensive, with average wholesale prices around $6 000–$8 000 per vial. Biosimilar versions of Romidepsin have not yet entered the market; the original drug’s patent life is still active, so no direct biosimilars are available. Generic versions may become available only after the patent expires.
Can patient‑assistance programs help offset the cost?
The manufacturer, Janssen Pharmaceuticals, offers a patient assistance program that can provide discounted or free medication to qualifying patients who meet income and insurance criteria. The program also offers co‑payment assistance for those with insurance coverage. Patients are advised to apply through the company’s website or call the support line.
What do real patients say about the financial impact?
Survey data from patient forums and advocacy groups show that many patients report high out‑of‑pocket expenses and stress over insurance coverage. Some patients use a combination of insurance, manufacturer assistance, and charitable grants to manage costs. Others express frustration when reimbursement decisions delay treatment, which can affect disease progression.